Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Exp Biol ; 2014 Dec; 52(12): 1165-1172
Article Dans Anglais | IMSEAR | ID: sea-153807

Résumé

Meclizine and caffeine combination is used for the treatment of morning sickness. Both compounds are teratogenic and caffeine is known to possess anti-fertility activity also. The present study was undertaken to evaluate the reproductive toxic effect of meclizine and caffeine combination. Three doses were taken for the study; low dose (LD; meclizine 3.7 mg/kg and caffeine 3 mg/kg) was selected from commercially available formulation, middle dose (MD; meclizine 37 mg/kg and caffeine 30 mg/kg) and high dose (HD; meclizine 370 mg/kg and caffeine 300 mg/kg). The mixture was administered 1-7 days and 8-14 days for fertility and embryotoxic studies respectively. Laparotomy was done on 10th day of gestation period. Number of implants and corpora lutea were counted, pre and post-implantation losses were determined. In embryo toxicity study fetuses were evaluated for external, skeletal and visceral examination. High dose was removed from both fertility and embryotoxicity studies due to its severe toxicity to the dam. Significant anti-fertility activity was observed at middle dose. Embryotoxicity study showed significant reduction in fetal body weight, body length and body mass index, dam body weight gain on gestation day 14. Absolute kidney weight in MD and absolute and relative spleen weight in both LD and MD were significantly reduced. There was no increase in external or internal congenital anomalies at both LD and MD. The, results suggest that prescription of meclizine and caffeine for morning sickness in early pregnancy should be reviewed carefully.


Sujets)
Malformations dues aux médicaments et aux drogues/étiologie , Administration par voie orale , Animaux , Poids/effets des médicaments et des substances chimiques , Caféine/administration et posologie , Caféine/toxicité , Relation dose-effet des médicaments , Association médicamenteuse , Consommation alimentaire/effets des médicaments et des substances chimiques , Développement embryonnaire/effets des médicaments et des substances chimiques , Femelle , Fécondité/effets des médicaments et des substances chimiques , Poids du foetus/effets des médicaments et des substances chimiques , Âge gestationnel , Antihistaminiques des récepteurs H1/administration et posologie , Antihistaminiques des récepteurs H1/toxicité , Rein/effets des médicaments et des substances chimiques , Rein/anatomopathologie , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Mâle , Méclozine/effets des médicaments et des substances chimiques , Méclozine/toxicité , Taille d'organe/effets des médicaments et des substances chimiques , Antagonistes des récepteurs purinergiques P1/administration et posologie , Antagonistes des récepteurs purinergiques P1/toxicité , Rat Wistar , Rate/effets des médicaments et des substances chimiques , Rate/anatomopathologie , Prise de poids/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
Détails de la recherche